Kamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, Sameer Bhargava, Andliena Tahiri, Jovana Klajic, Torben Lüders, Marie Fongård, Meh Sameen Nawaz, Tatjana Bosnjak-Olsen, Unn-Cathrin Edvardsen Buvarp, Aino Katri Johanna Rosenskiold, Nam Thi Nguyen, Tone Tysko Sletbak, Manouchehr Seyedzadeh, Knut Selsås, Alina Carmen Porojnicu, Helle Kristine Skjerven, Tone Hovda, Kristine Kleivi Sahlberg, Lilly Anne Torland, Marianne Lyngra, Clara Louise Hammarström, Elma Bahonjic Hönigsperger, John Christopher Noone, Silje Mathiassen, Antoni Hurtado, Shom Goel, Andrew Koff, Xavier Tekpli, Vessela N Kristensen, Jürgen Geisler
{"title":"NEOLETRIB试验:来曲唑和Ribociclib对ER阳性、HER2阴性乳腺癌的新辅助治疗。","authors":"Kamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, Sameer Bhargava, Andliena Tahiri, Jovana Klajic, Torben Lüders, Marie Fongård, Meh Sameen Nawaz, Tatjana Bosnjak-Olsen, Unn-Cathrin Edvardsen Buvarp, Aino Katri Johanna Rosenskiold, Nam Thi Nguyen, Tone Tysko Sletbak, Manouchehr Seyedzadeh, Knut Selsås, Alina Carmen Porojnicu, Helle Kristine Skjerven, Tone Hovda, Kristine Kleivi Sahlberg, Lilly Anne Torland, Marianne Lyngra, Clara Louise Hammarström, Elma Bahonjic Hönigsperger, John Christopher Noone, Silje Mathiassen, Antoni Hurtado, Shom Goel, Andrew Koff, Xavier Tekpli, Vessela N Kristensen, Jürgen Geisler","doi":"10.1080/14796694.2024.2377531","DOIUrl":null,"url":null,"abstract":"<p><p>Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be an appropriate alternative in selected patients. Thus, the NEOLETRIB trial evaluates the response of ER-positive, HER2-negative luminal A/B breast cancer to the combination of letrozole and ribociclib in the neoadjuvant setting. Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment.<b>Trial registration number:</b> NCT05163106 (ClinicalTrials.gov).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.\",\"authors\":\"Kamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, Sameer Bhargava, Andliena Tahiri, Jovana Klajic, Torben Lüders, Marie Fongård, Meh Sameen Nawaz, Tatjana Bosnjak-Olsen, Unn-Cathrin Edvardsen Buvarp, Aino Katri Johanna Rosenskiold, Nam Thi Nguyen, Tone Tysko Sletbak, Manouchehr Seyedzadeh, Knut Selsås, Alina Carmen Porojnicu, Helle Kristine Skjerven, Tone Hovda, Kristine Kleivi Sahlberg, Lilly Anne Torland, Marianne Lyngra, Clara Louise Hammarström, Elma Bahonjic Hönigsperger, John Christopher Noone, Silje Mathiassen, Antoni Hurtado, Shom Goel, Andrew Koff, Xavier Tekpli, Vessela N Kristensen, Jürgen Geisler\",\"doi\":\"10.1080/14796694.2024.2377531\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be an appropriate alternative in selected patients. Thus, the NEOLETRIB trial evaluates the response of ER-positive, HER2-negative luminal A/B breast cancer to the combination of letrozole and ribociclib in the neoadjuvant setting. Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment.<b>Trial registration number:</b> NCT05163106 (ClinicalTrials.gov).</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2024.2377531\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2377531","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
化疗是所有乳腺癌亚组的新辅助疗法,包括 ER 阳性和 HER2 阴性病例。不过,有研究表明,在选定的患者中,使用芳香化酶抑制剂联合 CDK4/6 抑制剂可能是一种合适的替代疗法。因此,NEOLETRIB试验评估了ER阳性、HER2阴性的管腔A/B型乳腺癌在新辅助治疗中对来曲唑和ribociclib联合治疗的反应。在6个月的治疗期间,将进行全面的分子生物学程序,包括对肿瘤活检组织进行连续单细胞RNA测序,并广泛收集血液样本、肿瘤活检组织和肠道微生物组标本。我们的研究结果有望有助于更好地选择可能从这种药物组合中获益的患者,并为了解这种治疗过程中肿瘤内部的变化提供新的视角:NCT05163106(ClinicalTrials.gov)。
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.
Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be an appropriate alternative in selected patients. Thus, the NEOLETRIB trial evaluates the response of ER-positive, HER2-negative luminal A/B breast cancer to the combination of letrozole and ribociclib in the neoadjuvant setting. Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment.Trial registration number: NCT05163106 (ClinicalTrials.gov).
期刊介绍:
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.